ACYCLOVIR THERAPY FOR MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN IMMUNOCOMPROMISED PATIENTS

Charles D. Mitchell; Sharron R. Gentry; James R. Boen; Bonnie Bean; Karl E. Groth; Henry H. Balfour

doi:10.1016/S0140-6736(81)92569-1

ACYCLOVIR THERAPY FOR MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN IMMUNOCOMPROMISED PATIENTS

Charles D. Mitchell, Sharron R. Gentry, James R. Boen, Bonnie Bean, Karl E. Groth, Henry H. Balfour

Research output: Contribution to journal › Article › peer-review

131 Scopus citations

Abstract

11 of 24 immunocompromised patients with mucocutaneous herpes simplex virus (HSV) infections were given intravenous acyclovir in a randomised double-blind placebo-controlled study. Patients receiving acyclovir experienced no major adverse effects. The median times to cessation of new lesion formation, lesion crusting, lesion healing, cessation of pain, and termination of viral shedding were shorter in the acyclovir-treated group than in the placebo group. The time-to-event probability curves for the acyclovir and placebo groups were significantly different for cessation of pain (p = 0.032) and termination of viral shedding (p = 0.004). The median times to termination of viral shedding were also statistically different (p = 0.045). Acyclovir seems to be a non-toxic and effective treatment for mucocutaneous HSV infections in immunocompromised patients.

Original language	English (US)
Pages (from-to)	1389-1392
Number of pages	4
Journal	The Lancet
Volume	317
Issue number	8235
DOIs	https://doi.org/10.1016/S0140-6736(81)92569-1
State	Published - Jun 27 1981
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/S0140-6736(81)92569-1

Fingerprint Dive into the research topics of 'ACYCLOVIR THERAPY FOR MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN IMMUNOCOMPROMISED PATIENTS'. Together they form a unique fingerprint.

Cite this

@article{080c7939b45b4380a445ab51d7421fdf,

title = "ACYCLOVIR THERAPY FOR MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN IMMUNOCOMPROMISED PATIENTS",

abstract = "11 of 24 immunocompromised patients with mucocutaneous herpes simplex virus (HSV) infections were given intravenous acyclovir in a randomised double-blind placebo-controlled study. Patients receiving acyclovir experienced no major adverse effects. The median times to cessation of new lesion formation, lesion crusting, lesion healing, cessation of pain, and termination of viral shedding were shorter in the acyclovir-treated group than in the placebo group. The time-to-event probability curves for the acyclovir and placebo groups were significantly different for cessation of pain (p = 0.032) and termination of viral shedding (p = 0.004). The median times to termination of viral shedding were also statistically different (p = 0.045). Acyclovir seems to be a non-toxic and effective treatment for mucocutaneous HSV infections in immunocompromised patients.",

author = "Mitchell, {Charles D.} and Gentry, {Sharron R.} and Boen, {James R.} and Bonnie Bean and Groth, {Karl E.} and Balfour, {Henry H.}",

year = "1981",

month = jun,

day = "27",

doi = "10.1016/S0140-6736(81)92569-1",

language = "English (US)",

volume = "317",

pages = "1389--1392",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "8235",

}

TY - JOUR

T1 - ACYCLOVIR THERAPY FOR MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN IMMUNOCOMPROMISED PATIENTS

AU - Mitchell, Charles D.

AU - Gentry, Sharron R.

AU - Boen, James R.

AU - Bean, Bonnie

AU - Groth, Karl E.

AU - Balfour, Henry H.

PY - 1981/6/27

Y1 - 1981/6/27

N2 - 11 of 24 immunocompromised patients with mucocutaneous herpes simplex virus (HSV) infections were given intravenous acyclovir in a randomised double-blind placebo-controlled study. Patients receiving acyclovir experienced no major adverse effects. The median times to cessation of new lesion formation, lesion crusting, lesion healing, cessation of pain, and termination of viral shedding were shorter in the acyclovir-treated group than in the placebo group. The time-to-event probability curves for the acyclovir and placebo groups were significantly different for cessation of pain (p = 0.032) and termination of viral shedding (p = 0.004). The median times to termination of viral shedding were also statistically different (p = 0.045). Acyclovir seems to be a non-toxic and effective treatment for mucocutaneous HSV infections in immunocompromised patients.

AB - 11 of 24 immunocompromised patients with mucocutaneous herpes simplex virus (HSV) infections were given intravenous acyclovir in a randomised double-blind placebo-controlled study. Patients receiving acyclovir experienced no major adverse effects. The median times to cessation of new lesion formation, lesion crusting, lesion healing, cessation of pain, and termination of viral shedding were shorter in the acyclovir-treated group than in the placebo group. The time-to-event probability curves for the acyclovir and placebo groups were significantly different for cessation of pain (p = 0.032) and termination of viral shedding (p = 0.004). The median times to termination of viral shedding were also statistically different (p = 0.045). Acyclovir seems to be a non-toxic and effective treatment for mucocutaneous HSV infections in immunocompromised patients.

UR - http://www.scopus.com/inward/record.url?scp=0019425636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019425636&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(81)92569-1

DO - 10.1016/S0140-6736(81)92569-1

M3 - Article

C2 - 6113352

AN - SCOPUS:0019425636

VL - 317

SP - 1389

EP - 1392

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8235

ER -